5John P, Renzo G, Giuseppe S, et al. Relative response of patients with myelodysplastic syndromes and other transfusion- dependent anaemias to deferasirox (ICL670): a 1-yr prospective study [J]. Eur J Haematol, 2008, 80(2) : 168- 176.
6Tehranchi R, Fadeel B, Schmidt-Mende J, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations [J]. Clin Cancer Res, 2005, 11 (17) : 6291- 6299.
7Eva HL, Tomas A, Yves Beguin, et al. Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony- Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase Ⅱ Study and Long-Term Follow-Up of 71 Patients [J]. Blood, 1998, 92(1): 68-75.
8Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience [ J ]. Ann Oncol, 2005, 16(1) : 139-145.
10Timo S, Timo T, Eeva J, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes [ J ]. Haematologica, 92 ( 8 ) : 1119-1122.
二级参考文献46
1姚尔固.新编白血病化疗学[M].天津：天津科学出版社,1996.12.
2Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodys-plastic syndrome: incidence, morphology, cytogen eticsand prognosis[J]. Ann Hematol,1993,66:117-122.
3Tuzuner N, Cox C, Rowe JM, et al. Hypocellular myelodysplastic syndrome(MDS):new proposals[J]. Br J Haematol,1995,91:612-617.
4Toyama K, Ohyashiki K, Yoshide Y, et al. Clinical and cytogenetic findings of myelodysplasic symodromes showing hypocellular bone marrow or min-imal dysplasia, incomparion with typical myelodysplastic syndrome[J], Int Haemato 1,1993,5:53-61.
5Nishimura M, Yamada T, Andoh T, et al. Granulocyte colonystimulating factor (G-GSb') dependent hematopoiesis with monosomy 7 in a patient with serere apiastic anemia after ATG/CsA/G-GSF combined therapy [J]. Int J Hematol,1998,68:203-211.
6Chery Willman,MD. 1 unviversity of New Mexico Cancer Center2325 Camino de Salud NE, Room 101 Albuquerque NM87131.
8Hellstrom-Lindberg E.Efficncy of erythropoietin in the myelodysplastic syndromes:a meta analysis of 205 patients from 17studies.Br J Haematol,1995,89:67.
9Hellstrom-Lindberg E,Ahlgren T,Begguin Y,et al.Treatment of the anemia of myelodysplastic syndromes with G-CSF plus erythropoietin:results from a randomized phase Ⅱ study and long term followup on 71 patients.Blood,1998,92:68.
10Economopoulos T,Mellou S,Papageorgiou E,et al.Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-marcophage colong-stimulating factor plus recombinant human erythropoietin.Leukemia,1999,13:1009.
8CASHEN A,SHAH A, HELGET A,et al. A phase Ⅰ pharmacokinetie trial of decitabine administered as a 3-hour infusion to patientswith acute myelogenous leukemia(AML) or myelodysp lastic syndrome (MDS) [ J ]. Blood ( ASH Annual Meeting Abstracts), 2005,106 : Abstract 1854.
9LUBBERT M, DASKALAKIS M, KUNZMANN R ,et al. Nonelonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine(decitabine) [ J ]. Leuk Res, 2004,28(12) :1267 - 1271.
10KANTARJIAN H, ISSA JP, ROSENFELD CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study [ J ]. Cancer, 2006, 106 ( 8 ) : 1794 - 1803.
